, Volume 29, Issue 1, pp 3–4 | Cite as

Alteplase deemed life saving and cost effective - GUSTO data

  • Tracey Langsdale
  • Carlene Todd
Newsletter Article


R outine substitution of alteplase for streptokinase for treating acute myocardial infarction (MI) is cost effective, according to Dr Daniel Mark and fellow investigators involved with the GUSTO trial * . 1 Their analysis suggests that the incremental cost-effectiveness value of alteplase is $US32 678/life-year saved. Putting this into context, using alteplase to treat the approximately 250 000 eligible patients in the US who present with acute MI each year would cost around $US500 million annually, but would yield 3.5 million additional years of life for alteplase recipients.


Streptokinase Misoprostol Alteplase Average Wholesale Prex Gusto Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 1995

Authors and Affiliations

  • Tracey Langsdale
  • Carlene Todd

There are no affiliations available

Personalised recommendations